Opdivo® (nivolumab), Yervoy® (ipilimumab) – Updated indication, accelerated approval converted to traditional approval
April 8, 2025 - The FDA announced the approval of Bristol Myers Squibb’s Opdivo (nivolumab) plus Yervoy (ipilimumab), for the treatment of adult and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC).
Top